We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2762 for:    effects of systemic NO

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00345150
First Posted: June 27, 2006
Last Update Posted: June 27, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Regional Hospital Holstebro
  Purpose
The study tests the hypothesis that systemic and renal nitric oxide synthesis is changed in essential hypertension by investigating the effects of a non selective nitric oxide inhibitor on renal hemodynamics and sodium excretion in patients with essential hypertension. The results are compared with a group of healthy subjects.

Condition Intervention Phase
Hypertension Drug: Ng-monomethyl-L-arginine (drug) Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Official Title: Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Resource links provided by NLM:


Further study details as provided by Regional Hospital Holstebro:

Estimated Enrollment: 30
Detailed Description:

The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:

  1. renal hemodynamics (renal plasma flow and glomerular filtration rate)
  2. renal sodium excretion
  3. lithium clearance and fractional lithium excretion
  4. plasma levels of vasoactive hormones
  5. blood pressure and heart rate
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Essential hypertension (blood pressure > 140/90) with no signs of secondary hypertension
  • P-creatinine < 200 µmol/L

Exclusion Criteria:

  • Anamnestic or clinical signs of heart disease, renal disease, liver disease, neoplastic disease, anemia or cerebro-vascular insult
  • Medication except antihypertensives
  • Drug or alcohol abuse
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00345150


Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Principal Investigator: Jesper N Bech, MD, Ph.D. Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
Study Chair: Erling B Pedersen, Professor Holstebro Hospital, 7500 Holstebro, Denmark
  More Information

ClinicalTrials.gov Identifier: NCT00345150     History of Changes
Other Study ID Numbers: MED.RES.HOS.1995.01.JNB
First Submitted: June 24, 2006
First Posted: June 27, 2006
Last Update Posted: June 27, 2006
Last Verified: June 2006

Keywords provided by Regional Hospital Holstebro:
hypertension
nitric oxide
renal hemodynamics

Additional relevant MeSH terms:
Physiological Effects of Drugs
Hypertension
Vascular Diseases
Cardiovascular Diseases
Nitric Oxide
omega-N-Methylarginine
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents
Enzyme Inhibitors